A Step Forward for Targeted Second-Line Pancreatic Cancer Treatment: Daraxonrasib Extends Overall Survival

Pancreatic cancer is difficult to treat, not only because it has often already spread by the time it is detected, but also because patients have very limited treatment options after first-line chemotherapy fails. The Phase 3 RASolute 302 trial now offers a rare and clear survival signal: the investigational once-daily oral drug daraxonrasib produced a median overall survival of 13.2 months in previously treated patients with metastatic pancreatic ductal adenocarcinoma, compared with 6.7 months in the chemotherapy group.

This randomized trial enrolled nearly 500 patients whose tumors had stopped responding to previous treatment. The results were published in The New England Journal of Medicine and presented at the 2026 American Society of Clinical Oncology Annual Meeting. In addition to the difference in survival, patients receiving daraxonrasib maintained pain control and quality of life for longer; data compiled by the American Cancer Society showed that treatment discontinuation due to side effects in the chemotherapy group was nearly ten times as frequent as in the daraxonrasib group.

Daraxonrasib is a RAS(ON) inhibitor that targets RAS proteins in their active state, blocking the transmission of cell-growth signals downstream. The significance of this strategy is that it does not target only a single KRAS mutation subtype, but may cover multiple RAS variants that drive pancreatic cancer. Approximately 90% of pancreatic ductal adenocarcinomas harbor KRAS-driven abnormalities, and this protein—with its smooth surface and long-standing reputation as difficult to drug—has remained a major gap in targeted cancer therapy.

An oral targeted drug is not necessarily free of toxicity. More consequential side effects in the trial included rash and mouth ulcers, along with diarrhea, nausea, and mucosal inflammation. Available data indicate that overall tolerability was better than with the comparator chemotherapy, but the full distribution of adverse events, the risks of long-term use, and whether different RAS subtypes derive the same degree of benefit still require more mature follow-up data.

The regulatory process has also begun. On July 22, 2026, the US Food and Drug Administration accepted the new drug application for daraxonrasib and granted priority review, but this does not mean the drug has been approved. At present, some eligible adults who cannot participate in clinical trials and lack effective treatment options may apply through their medical teams under an expanded access program. The drugmaker Revolution Medicines funded this Phase 3 study, and its financial interest and the need for subsequent independent validation should still be considered when interpreting the results.

This study concerned previously treated metastatic disease and does not establish that daraxonrasib is suitable for newly diagnosed patients or postoperative adjuvant therapy, or that it can replace all current chemotherapy. The study also showed that the drug’s efficacy may eventually diminish. The next hurdle, therefore, is not only securing approval, but also clarifying resistance mechanisms, determining the optimal treatment sequence, and establishing whether combination therapy can extend this survival advantage for longer.